CVA Family Office’s Calidi Biotherapeutics CLDI Stock Holding History

CVA Family Office’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	-$10	–	1820
2026 Q1	$10	Hold	3	–	–	﹤0.01%	1837
2025 Q4	$49	Hold	3	–	–	﹤0.01%	1283
2025 Q3	$64	Hold	3	–	–	﹤0.01%	1292
2025 Q2	$115	Hold	3	–	–	﹤0.01%	1271
2025 Q1	$283	Hold	3	–	–	﹤0.01%	1371
2024 Q4	$575	Hold	3	–	–	﹤0.01%	1194
2024 Q3	$570	Hold	3	–	–	﹤0.01%	1178
2024 Q2	$1K	Buy	+3	New	+$1.53K	﹤0.01%	1074

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CVA Family Office's CLDI Position: Q2 2026 in Review

CVA Family Office sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 3 shares — an estimated $10 sold.

CVA Family Office first reported a position in CLDI in Q2 2024 and held it in 8 quarters. The position peaked at $1K in Q2 2024. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

CVA Family Office reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
CVA Family Office sold 3 Calidi Biotherapeutics shares in Q2 2026, an estimated $10.
CVA Family Office first reported a position in Calidi Biotherapeutics in Q2 2024 and held it in 8 quarters.
CVA Family Office's Calidi Biotherapeutics position peaked at $1K in Q2 2024.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.